# NCT02268253 (NCT02268253)

> Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02268253
- Phase: PHASE1, PHASE2
- Status: COMPLETED
- Sponsor: Stemline Therapeutics, Inc.
- Conditions: Myelofibrosis; Chronic Myelomonocytic Leukemia
- Interventions: Tagraxofusp Injection
- Enrollment: 82
- Primary outcome: Number of Participants With Dose-limiting Toxicities (DLTs)
- Primary outcome: Objective Response Rate (ORR)

## Indexed commentary on NCT02268253 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct02268253